- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
Status: Open Not Enrolling
Investigator: Ericka Greene
Study Coordinator: Aramide Balogun
Phone: 713.441.6955
The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 ... Read more >
Status: Open Not Enrolling
Investigator: Ericka Greene
Study Coordinator: Aramide Balogun
Phone: 713.441.6955
This study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate the efficacy, safety and tolerability of remibrutinib in gMG patients who are on stable SOC treatment. Approximately 180 eligible participant ... Read more >
Status: Open Not Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator:
Phone:
NCT049747319 Brief Summary: This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Aramide Balogun
Phone: 713.441.6955
The study consists of a Screening Period of up to 6 weeks and 54-week Treatment Period. The anticipated duration is approximately 60 weeks. Participants will be randomized to receive an intravenous infusion of either del-desiran or placebo at ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Anjana Singh
Phone: 713.441.9120
Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Anjana Singh
Phone: 713.441.9120
The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work eval ... Read more >
Status: Open Not Enrolling
Investigator: Jun Li
Study Coordinator: Aramide Balogun
Phone: 713.441.6955
This study aims to look at the genetic differences between individuals with neurological disorders and healthy controls, and whether these genetic differences contribute to nerve conduction speeds. We expect that this study will identify a small ... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator: Delrose Vernon
Phone: 346.238.9068
Myasthenia gravis (MG) is a rare autoimmune disorder characterized by autoantibody responses that cause defective transmission of signals at the neuromuscular junction, resulting in a distinctive pattern of weakness. Patients with generalized MG ... Read more >
Status: Enrolling
Investigator: Bing Liao
Study Coordinator: KaDeesia Brown
Phone: 713.441.9120
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM ... Read more >